These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17590909)

  • 21. The contraceptive patch. Latest developments.
    Courtney K
    AWHONN Lifelines; 2006; 10(3):250-4. PubMed ID: 16792714
    [No Abstract]   [Full Text] [Related]  

  • 22. A clinical study of transdermal contraceptive patch in Thai women.
    Suwanmalee O; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S1-4. PubMed ID: 17726805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transdermal contraceptive patch: a new approach to hormonal contraception.
    Burkman RT
    Int J Fertil Womens Med; 2002; 47(2):69-76. PubMed ID: 11991433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Norelgestromin/ethinyl estradiol transdermal system.
    Taneepanichskul S
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S82-4. PubMed ID: 17722322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic overview of Ortho Evra/Evra.
    Abrams LS; Skee D; Natarajan J; Wong FA
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adhesion Evaluation of AG200-15: An Investigational Transdermal Contraceptive Delivery System.
    Ocheltree T; Wittes J; Case J; Tuley M; Krause I; Chiodo J; Garner EIO
    Adv Ther; 2019 Dec; 36(12):3381-3389. PubMed ID: 31602573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
    Sidney S; Cheetham TC; Connell FA; Ouellet-Hellstrom R; Graham DJ; Davis D; Sorel M; Quesenberry CP; Cooper WO
    Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A subdermal progestin implant for long-term contraception. The Medical Letter.
    Conn Med; 1991 Apr; 55(4):228. PubMed ID: 1906391
    [No Abstract]   [Full Text] [Related]  

  • 29. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.
    Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
    Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The statement of Polish Gynecological Society experts about transdermal contraceptive patch].
    Debski R; Karowicz-Bilińska A; Kotarski J; Kurzawa R; Nowak-Markwitz E; Pawelczyk L; Paszkowski T; Poreba R; Spaczyński M; Polish Gynaecologic Society
    Ginekol Pol; 2010 Jan; 81(1):69-73. PubMed ID: 20232704
    [No Abstract]   [Full Text] [Related]  

  • 32. Hormonal contraception: recent advances.
    Szarewski A
    J Fam Health Care; 2006; 16(2):35-6. PubMed ID: 16715750
    [No Abstract]   [Full Text] [Related]  

  • 33. High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.
    Jakimiuk AJ; Crosignani PG; Chernev T; Prilepskaya V; Bergmans P; Von Poncet M; Marelli S; Lee EJ
    Gynecol Endocrinol; 2011 Oct; 27(10):849-56. PubMed ID: 21142776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra).
    Zieman M
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Lasseter KC
    Contraception; 2001 Nov; 64(5):287-94. PubMed ID: 11777488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fertility control with norgestrel and ethynil estradiol. Report on continuing studies.
    Rice-Wray E; Cervantes A; Garcilazo J; Valenzuela P
    J Reprod Med; 1972 Aug; 9(2):45-9. PubMed ID: 5050402
    [No Abstract]   [Full Text] [Related]  

  • 37. [A transdermal form of combined hormonal contraceptives (EVRA)].
    Fanta M
    Ceska Gynekol; 2003 Oct; 68(5):341-5. PubMed ID: 14692356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of norgestrel-ethinyl oestradiol as a contraceptive.
    Tyler ET; Matsner EM; Gotlib MH; Levin M; Daniels T; Shimabukuro B; Dolman H; Elliot J
    J Reprod Fertil Suppl; 1968 Dec; 5():Suppl 5:109-16. PubMed ID: 5288229
    [No Abstract]   [Full Text] [Related]  

  • 39. Evra dose change: an air of secrecy.
    Prescrire Int; 2007 Jun; 16(89):107. PubMed ID: 17582928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA; Norman H; Doherty M; Walker AM
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.